The most interesting development of the week had nothing to do with Facebook or even Google losing its appeal against a €2.4bn fine from the European commission for abusing its monopoly of search to the detriment of competitors to its shopping service. The bigger deal was that DeepMind, a London-based offshoot of Google (or, to be precise, its holding company, Alphabet) was moving into the pharmaceutical business via a new company called Isomorphic Labs, the goal of which is grandly described as “reimagining the entire drug discovery process from first principles with an AI-first approach”.
Since they’re interested in first principles, let us first clarify that reference to AI. What it means in this context is not anything that is
Read more on theguardian.com